Clinical Trials

Galera’s investigational therapy rucosopasem manganese (rucosopasem) is a next-generation selective dismutase mimetic in clinical development to determine its ability to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with lung cancer and pancreatic cancer.

GRECO-1

Phase 1/2 Study of Rucosopasem in Combination with SBRT for NSCLC

GRECO-1 is a Phase 1/2, randomized, placebo-controlled study of rucosopasem in combination with stereotactic body radiation therapy (SBRT) in patients with early-stage, peripheral or centrally located non-small cell lung cancer (NSCLC).

GRECO-2

A Phase 2b Study of Rucosopasem in Combination with SBRT for Pancreatic Cancer

GRECO-2 is a Phase 2b randomized, double-blind, placebo-controlled study of rucosopasem in combination with stereotactic body radiation therapy (SBRT) in patients with nonmetastatic pancreatic cancer.

To identify clinical trials that match your diagnosis, treatment history and location, call 844-442-5372 or email .

Expanded Access Policy for Galera Therapeutics Inc. Investigational Therapies

Expanded Access Policy Statement